The relationship between predicted peptide-MHC class II affinity and T-cell activation in a HLA-DRbeta1*0401 transgenic mouse model
about
Mapping the Pareto optimal design space for a functionally deimmunized biotherapeutic candidateComputationally driven deletion of broadly distributed T cell epitopes in a biotherapeutic candidate.Protein deimmunization via structure-based design enables efficient epitope deletion at high mutational loadsInduction of arthritis in HLA-DR4-humanized and HLA-DQ8-humanized mice by human cartilage proteoglycan aggrecan but only in the presence of an appropriate (non-MHC) genetic background.Anti-citrullinated protein antibodies and their clinical utility in rheumatoid arthritis.Structure-based redesign of lysostaphin yields potent antistaphylococcal enzymes that evade immune cell surveillance.Systemic immunomodulation of autoimmune disease using MHC-derived recombinant TCR ligandsComputationally optimized deimmunization libraries yield highly mutated enzymes with low immunogenicity and enhanced activity.Arthritis induced by posttranslationally modified (citrullinated) fibrinogen in DR4-IE transgenic mice.Toward a multiscale model of antigen presentation in immunity.Citrulline-specific Th1 cells are increased in rheumatoid arthritis and their frequency is influenced by disease duration and therapy.The influence of MHC class II molecules containing the rheumatoid arthritis shared epitope on the immune response to aggrecan G1 and its peptides.An important step towards completing the rheumatoid arthritis cycle.Specificity of CD4 T-cell responses to aggrecan in BALB/c and DR1 transgenic mice.
P2860
Q28543006-8C65F527-1047-4E22-A21A-F345007A2E45Q30363065-775A6AB5-4764-499B-ABAD-0A90A1E994E1Q30371474-7AA71525-A35A-40A7-9F94-CF02754E2162Q31076623-67FABD54-00D6-4B04-983C-4383A5B51518Q34367709-5E98D3BF-4D75-46B2-BCF9-E385566B900CQ35751036-37DFA4C5-0AEA-4EA4-ADC2-9765BD27214DQ36107636-901B74EF-1A55-4BBE-B094-AB4EE1B6795DQ36399908-C8BD6885-5ABB-497E-AF20-990FD12A388AQ36537972-8214766C-14A9-440F-8895-4610E2903C1BQ36762526-DB0399F8-7A1D-4417-B855-86CC9FEB13F5Q42070930-6452B40F-C590-471F-B1B1-CF835EFD7066Q42617671-586AA164-6C8E-4A82-99AB-5667AEB67D0AQ43235823-7B9EF045-D30F-41BB-94EA-96AE4AA5FB9EQ55094295-9991CA82-2EE1-494E-B693-1B8CE6FAEAAF
P2860
The relationship between predicted peptide-MHC class II affinity and T-cell activation in a HLA-DRbeta1*0401 transgenic mouse model
description
2003 nî lūn-bûn
@nan
2003 թուականին հրատարակուած գիտական յօդուած
@hyw
2003 թվականին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
The relationship between predi ...... a1*0401 transgenic mouse model
@ast
The relationship between predi ...... a1*0401 transgenic mouse model
@en
The relationship between predi ...... a1*0401 transgenic mouse model
@nl
type
label
The relationship between predi ...... a1*0401 transgenic mouse model
@ast
The relationship between predi ...... a1*0401 transgenic mouse model
@en
The relationship between predi ...... a1*0401 transgenic mouse model
@nl
prefLabel
The relationship between predi ...... a1*0401 transgenic mouse model
@ast
The relationship between predi ...... a1*0401 transgenic mouse model
@en
The relationship between predi ...... a1*0401 transgenic mouse model
@nl
P2093
P2860
P356
P1476
The relationship between predi ...... a1*0401 transgenic mouse model
@en
P2093
Anthony M Jevnikar
David A Bell
Dequn Wang
Ewa Cairns
Jonathan A Hill
P2860
P2888
P356
10.1186/AR605
P407
P577
2003-01-01T00:00:00Z
P5875
P6179
1011450902